References

1. Lambert A, Loffroy R, Feydy A, Thévenin F, Merzoug V, Méjean N, Couaillier JF, Barral FG, Chevrot A, Drapé JL, Krausé D. Ostéoarthropathies d?origine endocrinienne. EMC. 2011; 31-175-B-10. PubMed | Google Scholar


2. Rousière M. De l?importance de prendre en charge l?ostéoporose. Presse Med. 2011;40(10):900?9. PubMed | Google Scholar


3. Wang Y, Nishida S, Elalieh HZ, Long RK, Halloran BP, Bikle DD. Role of IGF-I signaling in regulating osteoclastogenesis. J Bone Miner Res. 2006;21(9):1350-8. PubMed | Google Scholar


4. Raggatt LJ, Partridge NC. Cellular and molecular mechanisms of bone remodelling. J Biol Chem. 2010;285(33):25103-8. PubMed | Google Scholar


5. Van Staa TP. The pathogenesis, epidemiology and management of glucocorticoid induced osteoporosis. Calcif Tissue Int. 2006;79(3):129-37. PubMed | Google Scholar


6. Ernst M, Heath JK, Schmid C, Froesch RE, Rodan GA. Evidence for a direct effect of estrogen on bone cells in vitro. J Steroid Biochem. 1989;34(1-6):279-84. PubMed | Google Scholar


7. Rendina D, Gianfrancesco F, DeFilippo G. FSHR gene polymorphisms influence bone mineral density and bone turnover in postmenopausal women. Eur J Endocrinol. 2010;163(1):165-72. PubMed | Google Scholar


8. Gittoes NJ, Cooper MS. Primary hyperparathyroidism-is mild disease worth treating? Clin Med. 2010;10(1):45-9. Google Scholar


9. Silverberg SJ, Locker FG, Bilezikian JP. Vertebral osteopenia: a new indication for surgery in primary hyperparathyroidism. J Clin Endocrinol Metab. 1996;81(11):4007-12. PubMed | Google Scholar


10. Ribot C, Pouilles JM, Tremollieres F. Ostéoporose et hormones thyroidiennes. Rev Rhum. 2001;68 :722-6. PubMed | Google Scholar